mous
hepat
virus
mhv
use
agent
studi
experiment
infect
gastrointestin
central
nervou
system
mhv
member
coronaviru
group
anim
virus
virion
compos
three
structur
protein
major
glycoprotein
peplom
minor
glycoprotein
el
matrix
nucleocapsid
protein
n
order
better
understand
pathogenesi
immun
respons
induc
virus
attempt
made
alter
cours
infect
administ
monoclon
antibodi
specif
viral
structur
protein
buchmeier
colleagu
show
neutral
monoclon
antibodi
protect
mice
challeng
neurotrop
strain
jhmv
interestingli
mice
protect
acut
enceph
monoclon
antibodi
subsequ
develop
demyelin
wege
et
al
demonstr
monoclon
antibodi
protect
suckl
rat
investig
also
found
monoclon
antibodi
neutral
viru
inhibit
cell
fusion
protect
nakanaga
et
examin
monoclon
antibodi
reactiv
show
antin
monoclon
antibodi
protect
mice
lethal
induc
hepat
recent
lecomt
et
report
antin
monoclon
antibodi
neutral
vitro
presenc
complement
protect
mice
lethal
challeng
view
demonstr
antin
monoclon
antibodi
protect
rodent
infect
mhv
sought
determin
whether
monoclon
antibodi
specif
third
structur
protein
el
matrix
glycoprotein
could
alter
diseas
four
monoclon
antibodi
direct
el
glycoprotein
evalu
abil
neutral
viru
vitro
protect
mice
normal
fatal
viral
challeng
tabl
unless
state
otherwis
experi
use
male
mice
jackson
laboratori
bar
harbor
seroneg
mhv
given
pg
purifi
monoclon
antibodi
intraperiton
ip
day
intracerebr
ic
inocul
plaqueform
unit
pfu
strain
jhmv
ds
talbot
buchmeier
recent
shown
administr
murin
monoclon
antibodi
ip
result
signific
persist
plasma
antibodi
titer
mice
absenc
passiv
administ
antibodi
challeng
pfu
ic
strain
jhmv
ds
led
fatal
enceph
within
ol
day
mice
monoclon
antibodi
j
found
protect
mice
lethal
ic
challeng
tabl
howev
monoclon
antibodi
consist
fail
protect
mice
even
amount
antibodi
increas
pg
per
recipi
data
shown
protect
correl
igg
subclass
antibodi
protect
j
nonprotect
also
protect
correl
viru
neutral
vitro
presenc
complement
sinc
protect
monoclon
antibodi
j
neutral
nonneutr
vitro
respect
tabl
result
unexpect
sinc
except
two
monoclon
antibodi
report
nakanaga
et
previous
describ
antimhv
monoclon
antibodi
protect
viva
neutral
viru
vitro
order
determin
protect
antibodi
associ
uniqu
topograph
site
el
molecul
perform
competit
bind
studi
biotinyl
antibodi
use
previous
describ
method
regard
talbot
et
al
shown
el
least
two
major
antigen
site
talbot
et
measur
antibodi
one
site
el
found
signific
amount
antibodi
produc
experiment
infect
preliminari
studi
found
recogn
differ
antigen
site
el
furthermor
nonprotect
appear
bind
site
overlap
site
recogn
data
shown
thu
seem
unlik
protect
associ
bind
singl
critic
determin
el
although
find
correl
protect
high
rel
avid
monoclon
antibodi
tabl
l
addit
test
larger
panel
antiel
monoclon
antibodi
requir
evalu
signific
observ
initi
find
extend
detail
studi
viva
administ
grade
amount
purifi
j
found
minim
protect
dose
approxim
kg
result
similar
boer
et
al
found
pg
purifi
nonneutr
monoclon
antibodi
semliki
forest
viru
requir
protect
contrast
boer
eta
found
minim
amount
protect
neutral
monoclon
antibodi
pg
studi
also
shown
nonneutr
antivir
monoclon
antibodi
much
less
effect
neutral
monoclon
antibodi
base
amount
antibodi
need
protect
date
minimum
amount
protect
monoclon
antibodi
direct
n
viral
titer
brain
homogen
determin
limit
dilut
assay
dbt
cell
previous
describ
group
titer
express
mean
one
standard
deviat
pfu
viru
per
gram
tissu
mhv
protein
determin
absolut
unit
evalu
effect
delay
treatment
protect
antibodi
pg
given
group
five
mice
differ
time
rel
viral
challeng
day
antibodi
protect
mice
day
l
day
postinocul
day
one
five
mice
surviv
day
mice
surviv
sinc
mhv
replic
earli
mononuclear
cell
inflamm
present
brain
mice
day
pi
result
indic
monoclon
antibodi
simpli
prophylact
prevent
promot
recoveri
mice
enceph
initi
sinc
vitro
studi
indic
one
antiel
monoclon
antibodi
neutral
viru
presenc
complement
tabl
l
sought
determin
role
complement
might
play
viva
protect
mediat
passiv
administr
antibodi
issu
studi
two
approach
first
antibodymedi
protect
studi
bl
mice
normal
complement
bl
mice
defici
compon
complement
jackson
laboratori
monoclon
antibodi
pgmous
given
ip
day
pfu
given
ic
group
eight
mice
week
age
normal
complementdefici
mice
test
protocol
surviv
infect
contrast
two
eight
one
eight
bl
mice
surviv
without
antibodi
protect
second
experi
cobra
venom
factor
cvf
diamedix
miami
fl
use
deplet
old
mice
complement
compon
prior
ic
challeng
pfu
viru
mice
given
unit
cvf
intraven
serum
complement
measur
complementdepend
lysi
rabbit
red
blood
cell
coat
goat
antibodi
rabbit
erythrocyt
organon
teknikacappel
malvern
pa
mice
treat
cvf
found
deplet
four
group
four
mice
studi
viru
viru
plu
cvf
viru
plu
j
viru
plu
j
cvf
mice
receiv
viru
alon
group
mice
receiv
viru
plu
cvf
group
die
day
postinocul
hand
mice
given
pg
j
day
surviv
either
without
group
group
cvf
deplet
complement
thu
mice
either
genet
defici
complement
pharmacolog
deplet
complement
nevertheless
protect
antiel
monoclon
antibodi
normal
lethal
infect
result
suggest
complement
play
essenti
role
viva
protect
confer
antiel
monoclon
antibodi
order
monitor
viru
replic
viva
brain
viru
titer
passiv
protect
determin
day
postinocul
tabl
protect
antibodi
j
associ
modest
decreas
brain
viral
titer
day
infect
similar
note
protect
monoclon
antibodi
contrast
mice
protect
monoclon
antibodi
decreas
viral
titer
rel
unprotect
control
anim
data
indic
surviv
necessarili
depend
inhibit
net
viral
replic
rais
possibl
antibodi
may
protect
mice
alter
qualit
characterist
infect
cellular
distribut
viru
sever
viral
cytopathogen
explor
possibl
histolog
studi
nervou
system
unprotect
protect
mice
undertaken
sever
gener
neuropatholog
pattern
consist
note
unprotect
mice
viral
antigen
readili
demonstr
neuron
cerebr
cortex
hippocampu
day
inocul
fig
inflamm
mening
brain
parenchyma
perivascular
space
fig
c
usual
minim
moder
contrast
mice
protect
antibodi
show
much
less
involv
neuron
fig
b
although
inflammatori
infiltr
mening
brain
parenchyma
perivascular
space
often
sever
fig
subacut
day
protect
mice
show
rarefact
intens
inflamm
white
matter
typic
demyelin
fig
e
studi
demonstr
administr
monoclon
antibodi
specif
el
protein
mhv
protect
mice
lethal
viral
challeng
mechan
protect
howev
remain
uncertain
evid
gather
indic
antiel
monoclon
antibodi
protect
virtu
particular
antibodi
isotyp
mean
recognit
specif
topograph
site
e
neither
vitro
neutral
reduct
viral
replic
viva
appear
essenti
characterist
protect
antibodi
similarli
complement
activ
viva
also
appear
necessari
protect
hand
histolog
studi
reveal
distinct
find
may
indic
antiel
monoclon
antibodi
protect
mice
challeng
found
protect
mice
increas
parenchym
perivascular
cellular
infiltr
compar
unprotect
control
similar
result
report
nakanaga
et
suggest
passiv
antimhv
antibodi
administr
enhanc
cellmedi
immun
one
mechan
antibodi
may
enhanc
cellmedi
immun
virus
involv
bind
fc
receptor
antigen
present
cell
specif
receptor
cell
experiment
effector
function
cell
shown
increas
mean
administr
antibodi
hepat
b
viru
anoth
signific
histolog
find
anim
protect
antiel
monoclon
antibodi
neuron
rel
spare
observ
consist
buchmeier
colleagu
found
mice
treat
monoclon
antibodi
challeng
show
littl
involv
neuron
mice
also
surviv
show
subacut
demyelin
contrast
mice
receiv
antibodi
acut
fatal
necrot
encephalomyel
neuronophagia
studi
parallel
temperaturesensit
plaqu
morpholog
antigen
variant
show
increas
propens
demyelin
thu
appear
variabl
allow
anim
surviv
initi
enceph
perhap
attenu
viral
cytopathogen
neuron
permit
subacut
demyelin
manifest
similarli
harti
et
demonstr
nonneutr
antibodi
lactat
dehydrogenaseelev
viru
protect
mice
motor
neuron
diseas
although
level
viral
replic
unchang
studi
antibodi
appear
block
infect
neuron
effect
infect
nonneuron
central
nervou
system
cell
taken
togeth
find
consist
observ
neuron
usual
critic
target
highli
neurovirul
virus
nonneutr
monoclon
antibodi
also
shown
protect
anim
neurotrop
virus
includ
sindbi
semliki
forest
western
equin
enceph
venezuelan
equin
enceph
st
loui
enceph
id
herp
simplex
vesicular
stomat
yellow
fever
virus
find
contrast
prior
studi
use
monoval
monoclon
antibodi
conclud
antiel
antibodi
protect
mhv
challeng
differ
studi
previou
report
may
reflect
antibodi
test
virus
use
challeng
experiment
variabl
knowledg
result
first
demonstr
antibodi
direct
viral
matrix
protein
protect
mice
viral
challeng
thu
immun
respons
matrix
minor
glycoprotein
almost
entir
embed
virion
envelop
might
expect
highli
immunogen
may
nevertheless
influenc
outcom
diseas
observ
may
signific
implic
design
vaccin
understand
antivir
immun
grate
ligaya
pen
cindi
fabriciusseg
excel
technic
assist
carol
flore
excel
editori
help
manuscript
thank
dr
wendi
gilmor
help
critic
suggest
work
support
public
health
servic
grant
